I 
112TH CONGRESS 
1ST SESSION H. R. 2521 
To reduce human exposure to endocrine-disrupting chemicals, and for other 
purposes. 
IN THE HOUSE OF REPRESENTATIVES 
JULY 13, 2011 
Mr. MORAN (for himself, Mr. HINCHEY, Mr. CONNOLLY of Virginia, Ms. NOR-
TON, Mr. GEORGE MILLER of California, Ms. RICHARDSON, Mr. GRI-
JALVA, Ms. SCHAKOWSKY, Mrs. LOWEY, Mr. RUSH, Mrs. CAPPS, Mr. 
MCGOVERN, and Mr. PRICE of North Carolina) introduced the following 
bill; which was referred to the Committee on Energy and Commerce 
A BILL 
To reduce human exposure to endocrine-disrupting chemicals, 
and for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Endocrine-Disrupting 
Chemicals Exposure Elimination Act of 2011’’. 
SEC. 2. TABLE OF CONTENTS. 
The table of contents of this Act is as follows: 
Sec. 1. Short title. 
Sec. 2. Table of contents. 
Sec. 3. Findings. 
Sec. 4. Definitions. 
VerDate Mar 15 2010 
04:25 Jul 14, 2011
Jkt 099200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6211
E:\BILLS\H2521.IH
H2521
smartinez on DSK6TPTVN1PROD with BILLS
Sec. 5. Tiering applicable to levels of evidence and concern. 
TITLE I—RESEARCH ON ENDOCRINE-DISRUPTING CHEMICALS 
Sec. 101. National toxicology program activities. 
Sec. 102. Research program of national institute of environmental health 
sciences. 
TITLE II—REDUCING EXPOSURE TO ENDOCRINE-DISRUPTING 
CHEMICALS 
Sec. 201. Federal agency action. 
Sec. 202. Citizen suits. 
TITLE III—TRAINING 
Sec. 301. Training in fields related to the prevention of endocrine disruption. 
TITLE IV—MISCELLANEOUS 
Sec. 401. Authorization of appropriations. 
SEC. 3. FINDINGS. 
The Congress finds as follows: 
(1) There is growing evidence that the human 
endocrine system is extremely sensitive to particular 
chemicals. 
(2) Numerous studies show links between par-
ticular chemicals and hormone functions in animals 
and in humans, and those links have been further 
connected to numerous disorders. 
(3) A targeted research and evaluation program 
on suspected endocrine-disrupting chemicals would 
establish greater scientific certainty with respect to 
the linkage of particular chemicals with endocrine 
system effects. 
VerDate Mar 15 2010 
04:25 Jul 14, 2011
Jkt 099200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H2521.IH
H2521
smartinez on DSK6TPTVN1PROD with BILLS
(4) Credible linkages established by this re-
search will be the basis for regulation under authori-
ties including— 
(A) the Federal Food, Drug, and Cosmetic 
Act; 
(B) the Toxic Substances Control Act; 
(C) the Safe Drinking Water Act; 
(D) the Food Quality Protection Act; 
(E) the Clean Air Act; 
(F) the Clean Water Act; and 
(G) the Federal Insecticide, Fungicide, and 
Rodenticide Act. 
(5) Such research, information availability, and 
scientific perspective would also promote voluntary 
actions to reduce exposure to these harmful chemi-
cals through market forces. 
(6) There is a need to educate the public on the 
results of research on endocrine-disrupting chemicals 
so that manufacturers, processors, retailers, and in-
dividual consumers can make informed decisions 
about potential exposure to harmful chemicals. 
(7) People should be protected from chemicals 
that are found to have endocrine-disrupting effects. 
(8) Animal testing should be reduced to the 
minimum necessary with the goal of transitioning to 
VerDate Mar 15 2010 
04:25 Jul 14, 2011
Jkt 099200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H2521.IH
H2521
smartinez on DSK6TPTVN1PROD with BILLS
a predominantly nonanimal paradigm as articulated 
in the 2007 National Research Council report ‘‘Tox-
icity Testing in the Twenty-First Century: A Vision 
and a Strategy’’. 
SEC. 4. DEFINITIONS. 
In this Act: 
(1) The term ‘‘chemical’’ means an individual 
chemical, a combination of chemicals, or a mixture 
of chemicals. 
(2) The term ‘‘Director’’ means the Director of 
the National Institute of Environmental Health 
Sciences. 
(3) The term ‘‘endocrine-disrupting chemical’’ 
means a chemical that interrupts, alters, interferes 
with, disturbs, or otherwise changes the human en-
docrine system or cell functioning. 
(4) The term ‘‘Endocrine Disruption Expert 
Panel’’, ‘‘Expert Panel’’, or ‘‘Panel’’ means the En-
docrine Disruption Expert Panel established under 
section 101(a)(2). 
SEC. 5. TIERING APPLICABLE TO LEVELS OF EVIDENCE 
AND CONCERN. 
In identifying, determining, or making a finding with 
respect to a level of evidence or a level of concern under 
this Act (including sections 101(a)(3), 101(a)(4), 
VerDate Mar 15 2010 
04:25 Jul 14, 2011
Jkt 099200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H2521.IH
H2521
smartinez on DSK6TPTVN1PROD with BILLS
101(b)(2)(C), and 201(a)(2)(B)), the Director or the Ex-
pert Panel, as applicable, shall select from among the fol-
lowing levels: 
(1) High. 
(2) Substantial. 
(3) Minimal. 
(4) None. 
TITLE I—RESEARCH ON ENDO-
CRINE-DISRUPTING 
CHEMI-
CALS 
SEC. 101. NATIONAL TOXICOLOGY PROGRAM ACTIVITIES. 
(a) IN GENERAL.—As part of the National Toxi-
cology Program, the Director, in consultation with the Na-
tional Toxicology Program Board of Scientific Counselors 
(or any successor board or committee), shall— 
(1) establish and implement a research program 
designed to strengthen the scientific basis of infor-
mation used by Federal agencies to understand the 
effects of, and reduce human exposure to, endocrine- 
disrupting chemicals; 
(2) establish (subject to subsection (b)(1)) an 
Endocrine Disruption Expert Panel and direct the 
Panel to consider and report to the Director on 
issues related to identification, classification, or eval-
VerDate Mar 15 2010 
04:25 Jul 14, 2011
Jkt 099200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H2521.IH
H2521
smartinez on DSK6TPTVN1PROD with BILLS
uation of endocrine-disrupting chemicals as specified 
in subsection (b)(2); 
(3) for each chemical determined by the Direc-
tor to be a potential or actual endocrine-disrupting 
chemical— 
(A) identify the level of evidence that such 
chemical is or may be an endocrine-disrupting 
chemical; 
(B) identify the level of concern that such 
chemical may disrupt the human endocrine sys-
tem; and 
(C) identify the pathways of exposure to 
the chemical for humans and animals; and 
(4) not later than 2 years after the date of the 
enactment of this Act, and every 2 years thereafter, 
provide to the Congress and each relevant Federal 
agency and make publicly available— 
(A) an up-to-date list specifying each 
chemical identified by the Director to be a po-
tential or actual endocrine-disrupting chemical 
and identifying the level of evidence that the 
chemical disrupts the human endocrine system, 
the level of concern that the chemical disrupts 
the human endocrine system, and the pathways 
VerDate Mar 15 2010 
04:25 Jul 14, 2011
Jkt 099200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H2521.IH
H2521
smartinez on DSK6TPTVN1PROD with BILLS
of exposure to the chemical for humans and 
animals; and 
(B) a report on— 
(i) the National Toxicology Program’s 
activities 
pertaining 
to 
endocrine-dis-
rupting chemicals; and 
(ii) the activities of Federal agencies 
with respect to endocrine-disrupting chemi-
cals, including actions taken or expected to 
be taken pursuant to section 201. 
(b) EXPERT PANEL.— 
(1) APPOINTMENT.—The Director, in consulta-
tion with the National Toxicology Program Board of 
Scientific Counselors (or any successor board or 
committee), shall appoint the members of the Endo-
crine Disruption Expert Panel (established under 
subsection (a)(2)) from among individuals who— 
(A) have established expertise in the field 
of endocrine disruption research by publishing 
research in peer-reviewed literature and have 
received 
Federal 
endocrine-research-related 
funding within the 2 years preceding appoint-
ment under this subsection; 
(B) provide assurances they will perform 
their duties in a manner free of conflicts of in-
VerDate Mar 15 2010 
04:25 Jul 14, 2011
Jkt 099200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H2521.IH
H2521
smartinez on DSK6TPTVN1PROD with BILLS
terest, as determined by the Director, including 
by complying with section 208 of title 18, 
United States Code; and 
(C) represent diverse disciplines, which 
may include endocrinology, developmental and 
neurological biology, embryology, biochemistry, 
physiology, epidemiology, endocrine-driven on-
cology, in vitro and computational toxicology, 
and medical research. 
(2) DUTIES.—During each of the 10 years fol-
lowing the date of the enactment of this Act, the Ex-
pert Panel shall— 
(A) consider, and report to the Director 
on, issues related to identification, classifica-
tion, or evaluation of not more than 10 endo-
crine-disrupting chemicals or groups of endo-
crine-disrupting chemicals; 
(B) evaluate existing research aimed at un-
derstanding the biological pathways in humans 
by which endocrine-disrupting chemicals operate 
and identify future research priorities as appro-
priate; and 
(C) maintain a list that identifies chemi-
cals of concern for endocrine disruption effects 
VerDate Mar 15 2010 
04:25 Jul 14, 2011
Jkt 099200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\H2521.IH
H2521
smartinez on DSK6TPTVN1PROD with BILLS
and includes findings, based upon peer-reviewed 
studies and other relevant data, regarding— 
(i) whether a chemical is a potential 
or actual endocrine-disrupting chemical; 
(ii) the level of evidence that the 
chemical is or may be an endocrine-dis-
rupting chemical; 
(iii) the level of concern that the 
chemical may disrupt the human endocrine 
system; 
(iv) the pathways of exposure to the 
chemical for humans and animals; and 
(v) the need for additional data, as-
says, testing, or research to determine the 
level of concern associated with the chemi-
cal’s potential to disrupt the human endo-
crine system. 
(3) REPORT.—The Expert Panel shall provide 
to the Director and make publicly available a bien-
nial report on the Panel’s activities, including an up- 
to-date version of the list under paragraph (2)(C). 
(c) PETITIONS.— 
(1) IN GENERAL.—Any State, Tribe, local gov-
ernment, Federal agency, or person may petition the 
Director— 
VerDate Mar 15 2010 
04:25 Jul 14, 2011
Jkt 099200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6201
E:\BILLS\H2521.IH
H2521
smartinez on DSK6TPTVN1PROD with BILLS
(A) to determine whether a chemical 
should be identified by the National Toxicology 
Program to be a potential or actual endocrine- 
disrupting chemical and included in the list 
under subsection (a)(4)(A); or 
(B) to reclassify a chemical, revise a find-
ing, or amend any other determination of the 
National Toxicology Program based upon new 
information. 
(2) RULES.—The Director shall adopt rules 
that provide for— 
(A) the form and procedure for filing of 
petitions under paragraph (1); and 
(B) the procedural rights of entities filing 
such petitions. 
(d) NO JUDICIAL REVIEW.—A listing, finding, or 
other determination under this section shall not be subject 
to judicial review, nor to correction under section 515 of 
the Treasury and General Government Appropriations 
Act, 2001 (commonly referred to as the ‘‘Information 
Quality Act’’). 
VerDate Mar 15 2010 
04:25 Jul 14, 2011
Jkt 099200
PO 00000
Frm 00010
Fmt 6652
Sfmt 6201
E:\BILLS\H2521.IH
H2521
smartinez on DSK6TPTVN1PROD with BILLS
SEC. 102. RESEARCH PROGRAM OF NATIONAL INSTITUTE 
OF ENVIRONMENTAL HEALTH SCIENCES. 
Subpart 12 of part C of title IV of the Public Health 
Service Act (42 U.S.C. 2851 et seq.) is amended by adding 
at the end the following: 
‘‘SEC. 463C. ENDOCRINE DISRUPTION RESEARCH PRO-
GRAM. 
‘‘(a) PROGRAM.—The Director of the Institute shall 
conduct and support a research program, to be known as 
the Endocrine Disruption Research Program, to improve 
the understanding of how chemicals can disrupt the 
human endocrine system. Such program shall— 
‘‘(1) be designed— 
‘‘(A) to develop the information needed by 
Federal agencies to understand chemical dis-
ruption of the endocrine system and reduce 
human and animal exposure to endocrine-dis-
rupting chemicals; 
‘‘(B) to understand the cellular pathways 
in 
humans 
by 
which 
endocrine-disrupting 
chemicals are able to cause adverse effects; and 
‘‘(C) to use laboratory practices that will 
produce data that are sufficiently accurate and 
reproducible to be used for regulatory decisions; 
‘‘(2) include research to design, develop, and 
validate appropriately sensitive tests to screen and 
VerDate Mar 15 2010 
04:25 Jul 14, 2011
Jkt 099200
PO 00000
Frm 00011
Fmt 6652
Sfmt 6201
E:\BILLS\H2521.IH
H2521
smartinez on DSK6TPTVN1PROD with BILLS
identify chemicals capable of disrupting the human 
endocrine system; 
‘‘(3) address the full range of possible human 
health impacts, including but not limited to— 
‘‘(A) male and female developmental and 
reproductive disorders; 
‘‘(B) brain and neurobehavioral disorders; 
‘‘(C) metabolic syndrome, prediabetes, dia-
betes, improper glucose and fat metabolism, 
obesity, and cardiovascular disorders; 
‘‘(D) effects on the pituitary, hypothala-
mus, hippocampus, thyroid, adrenal, immune, 
bone, cardiovascular, and other endocrine or-
gans and systems throughout all life stages; 
‘‘(E) hormonally driven cancer; and 
‘‘(F) other related effects; 
‘‘(4) consider the potential for additive and syn-
ergistic effects; 
‘‘(5) be carried out using a multidisciplinary ap-
proach to ensure connections among multiple levels, 
including the molecular, organ, and whole animal or 
human levels; 
‘‘(6) refine computational modeling tools to in-
tegrate cellular pathway data into a dose-response 
framework for risk assessment; 
VerDate Mar 15 2010 
04:25 Jul 14, 2011
Jkt 099200
PO 00000
Frm 00012
Fmt 6652
Sfmt 6201
E:\BILLS\H2521.IH
H2521
smartinez on DSK6TPTVN1PROD with BILLS
‘‘(7) identify biomarkers of exposure and effect 
that can be further developed and translated for use 
in human epidemiological and public health studies 
focused on defining the role of endocrine-disrupting 
chemicals in disease etiology across the lifespan; and 
‘‘(8) ensure that research or testing involving 
living animals is carried out only when equally effec-
tive and reliable alternative approaches for obtaining 
the result sought are not readily available. 
‘‘(b) WORKSHOPS AND FORA.—The Director of the 
Institute may conduct workshops and fora and provide in-
formation on the health effects associated with chemicals 
that may disrupt the endocrine system in order to— 
‘‘(1) identify chemicals for research under sub-
section (a); 
‘‘(2) strategize on approaches for the develop-
ment of sensitive tests to screen chemicals for endo-
crine-disrupting activity using assays; 
‘‘(3) review the state of the science on endo-
crine-disrupting chemicals and provide recommenda-
tions for a research, testing, and training agenda; 
and 
‘‘(4) educate attendees about endocrine-dis-
rupting chemicals. 
‘‘(c) DEFINITIONS.—In this section: 
VerDate Mar 15 2010 
04:25 Jul 14, 2011
Jkt 099200
PO 00000
Frm 00013
Fmt 6652
Sfmt 6201
E:\BILLS\H2521.IH
H2521
smartinez on DSK6TPTVN1PROD with BILLS
‘‘(1) The term ‘chemical’ means an individual 
chemical, a combination of chemicals, or a mixture 
of chemicals. 
‘‘(2) The term ‘endocrine-disrupting chemical’ 
means a chemical that interrupts, alters, interferes 
with, disturbs, or otherwise changes the human or 
animal endocrine system or its functioning.’’. 
TITLE II—REDUCING EXPOSURE 
TO 
ENDOCRINE-DISRUPTING 
CHEMICALS 
SEC. 201. FEDERAL AGENCY ACTION. 
(a) RESPONSE TO LIST AND STRATEGY.— 
(1) IN GENERAL.—Not later than 90 days after 
receiving each biennial list, strategy, and report 
under section 101(a)(4), each Federal agency with 
regulatory authority over any chemical included on 
the list shall prepare and publish a written response 
to the list and strategy. 
(2) CONTENTS.—At a minimum, a Federal 
agency’s response under paragraph (1) shall— 
(A) include an evaluation of the findings 
and determinations of the National Toxicology 
Program pertaining to each listed chemical sub-
ject to the agency’s regulatory authority; and 
VerDate Mar 15 2010 
04:25 Jul 14, 2011
Jkt 099200
PO 00000
Frm 00014
Fmt 6652
Sfmt 6201
E:\BILLS\H2521.IH
H2521
smartinez on DSK6TPTVN1PROD with BILLS
(B) adopt or modify, as scientifically ap-
propriate, each finding of the National Toxi-
cology Program pertaining to— 
(i) whether any such chemical dis-
rupts or may disrupt the human endocrine 
system; 
(ii) the level of concern associated 
with any such chemical’s potential to dis-
rupt the human endocrine system; and 
(iii) the pathways of exposure to the 
chemical for humans and animals. 
(b) MINIMAL LEVEL OF CONCERN.—If the Director 
finds under section 101(a)(3)(A) that there is at least a 
minimal level of concern that a chemical may disrupt the 
human endocrine system— 
(1) each Federal agency with regulatory author-
ity over the chemical shall— 
(A) develop a strategy for reducing human 
exposure to the chemical; 
(B) make the strategy publicly available 
not later than 180 days after the agency re-
ceives the Director’s finding; and 
(C) include in the strategy methods to pro-
mote voluntary actions by industry for reducing 
human exposure to the chemical; and 
VerDate Mar 15 2010 
04:25 Jul 14, 2011
Jkt 099200
PO 00000
Frm 00015
Fmt 6652
Sfmt 6201
E:\BILLS\H2521.IH
H2521
smartinez on DSK6TPTVN1PROD with BILLS
(2) each Federal agency with regulatory author-
ity over the chemical shall take action under such 
authority, such as further testing or issuance of or-
ders, regulations, or public notices, to reduce or 
eliminate human exposure to the chemical. 
(c) HIGHEST LEVEL OF CONCERN.— 
(1) PROHIBITION.—Beginning on the date that 
is 24 months after the Director makes publicly avail-
able a finding under section 101(a)(3)(B) that there 
is a high level of concern that a chemical may dis-
rupt the human endocrine system, it shall be unlaw-
ful to use the chemical in a manner in or affecting 
interstate commerce unless the pathway to human 
exposure is mitigated before or in conjunction with 
such use. 
(2) FEDERAL AGENCY ACTION.—Not later than 
24 months after the Director makes publicly avail-
able such a finding under section 101(a)(3)(B), each 
Federal agency with regulatory authority over the 
chemical subject to the finding shall establish regu-
lations or take other actions to implement the prohi-
bition in paragraph (1) with respect to such chem-
ical. 
(d) AGGREGATED COMPUTATIONAL TOXICOLOGY RE-
SOURCES DATABASES.—The Administrator of the Envi-
VerDate Mar 15 2010 
04:25 Jul 14, 2011
Jkt 099200
PO 00000
Frm 00016
Fmt 6652
Sfmt 6201
E:\BILLS\H2521.IH
H2521
smartinez on DSK6TPTVN1PROD with BILLS
ronmental Protection Agency shall include the findings 
and determinations of the National Toxicology Program 
pertaining to endocrine-disrupting chemicals in the Aggre-
gated Computational Toxicology Resource (ACToR) data-
bases (or any successor databases) to the extent otherwise 
permitted by law including any restrictions on the disclo-
sure of confidential business information. 
SEC. 202. CITIZEN SUITS. 
(a) AUTHORITY TO BRING CIVIL ACTIONS.—Any 
State, Tribe, local government, or person may commence 
a civil action to prevent or restrain a prohibited use of 
a chemical in violation of section 201. 
(b) JURISDICTION.—The United States courts of ap-
peal shall have exclusive original jurisdiction over such ac-
tion. 
TITLE III—TRAINING 
SEC. 301. TRAINING IN FIELDS RELATED TO THE PREVEN-
TION OF ENDOCRINE DISRUPTION. 
The Director shall establish a program to support, 
directly or by making grants, graduate and postdoctoral 
training in fields related to the study and prevention of 
endocrine disruption. 
VerDate Mar 15 2010 
04:25 Jul 14, 2011
Jkt 099200
PO 00000
Frm 00017
Fmt 6652
Sfmt 6201
E:\BILLS\H2521.IH
H2521
smartinez on DSK6TPTVN1PROD with BILLS